Abionic’s sepsis test | A diagnosis solution for the new Coronavirus
12.03.2020
Share this article
Abionic’s R&D focuses on the development of an early sepsis diagnosis solution | A tool for Coronavirus identification
Abionic, based at the Biopole in Lausanne, has developed an innovative solution enabling the diagnosis of sepsis within 5 minutes through the use of a single drop of blood.
Sepsis is also one of the main complications linked to COVID-19. Abionic’s solution could therefore be used to identify high risk patients infected by the new Coronavirus.